Calendar

pharmadog

Week of Apr 6, 2026

Apr 6, 2026approval128d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

full page →pembrolizumab →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: MICRO LABS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: MICRO LABS. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: BIOCON PHARMA. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: MSN. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: MSN. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: AJANTA PHARMA LTD. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — FDA approvalDAPAGLIFLOZIN

Sponsor: AUROBINDO PHARMA. Form: TABLET

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalMicro Labs Ltd

Sponsor: SUN PHARM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalMSN Pharmaceuticals Inc

Sponsor: INVENTIA. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: MACLEODS PHARMS LTD. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalMSN Pharmaceuticals Inc

Sponsor: AIZANT. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoKEYTRUDA QLEX (PEMBROLIZUMAB) — FDA approval(berahyaluronidase alfa + pembrolizumab)

Sponsor: MERCK SHARP DOHME. Form: INJECTABLE. Route: INJECTION

full page →(berahyaluronidase alfa + pembrolizumab) →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: LUPIN LTD. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: MSN. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: CIPLA. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: CIPLA LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: TORRENT. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalTeva Pharmaceuticals USA Inc

Sponsor: TEVA PHARMS USA. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalMSN Pharmaceuticals Inc

Sponsor: ALKEM LABS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: MACLEODS PHARMS LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalMicro Labs Ltd

Sponsor: ALKEM LABS LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: LUPIN LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalZydus Therapeutics Inc

Sponsor: ZYDUS PHARMS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: TEVA PHARMS USA INC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — FDA approvalDAPAGLIFLOZIN

Sponsor: CIPLA. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoPAROXETINE HYDROCHLORIDE — FDA approvalPAROXETINE HYDROCHLORIDE

Sponsor: AUROBINDO PHARMA USA. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →PAROXETINE HYDROCHLORIDE →fda approvals ↗

Apr 6, 2026approval128d agoPAROXETINE HYDROCHLORIDE — FDA approvalPAROXETINE HYDROCHLORIDE

Sponsor: AUROBINDO PHARMA USA. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →PAROXETINE HYDROCHLORIDE →fda approvals ↗

Apr 6, 2026approval128d agoDAPAGLIFLOZIN — FDA approvalDAPAGLIFLOZIN

Sponsor: SANDOZ. Form: TABLET. Route: ORAL

full page →DAPAGLIFLOZIN →fda approvals ↗

Apr 6, 2026approval128d agoPAROXETINE HYDROCHLORIDE — FDA approvalPAROXETINE HYDROCHLORIDE

Sponsor: AUROBINDO PHARMA USA. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →PAROXETINE HYDROCHLORIDE →fda approvals ↗

Apr 6, 2026approval128d agoPAROXETINE HYDROCHLORIDE — FDA approvalPAROXETINE HYDROCHLORIDE

Sponsor: AUROBINDO PHARMA USA. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →PAROXETINE HYDROCHLORIDE →fda approvals ↗

Apr 6, 2026grant128d agoUNIVERSITY OF PITTSBURGH AT PITTSBURGH — Interleukin 33 signaling beneficially regulates pathologic glia in multiple s...

AI grant. $157,788. PI: Sachin Gadani

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF CALIFORNIA, SAN FRANCISCO — Development of a Humanized IL33 MouseUniversity of California San Francisco

AI grant. $174,824. PI: Erin D. Gordon

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIV OF NORTH CAROLINA CHAPEL HILL — A Trial of Upadacitinib for Non-responsive Eosinophilic esophagitis (ATUNE)AbbVie Inc.

DK grant. $781,365. PI: Seema S Aceves

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF MARYLAND BALTIMORE — Modeling the Vaginal Microbiome: Predicting BV Recurrence and Identifying Pre...

AI grant. $427,625. PI: Johanna B. Holm

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF CALIFORNIA, SAN DIEGO — Investigating the role of A-to-I RNA editing by ADARs in corticogenesis using...University of California San Diego

MH grant. $43,784. PI: Summer Rose Fair

full page →nih reporter ↗

Apr 6, 2026grant128d agoYALE UNIVERSITY — Novel Gene Variants of ZFYVE21 and Dysregulated Innate Immunity

AI grant. $778,828. PI: CLARA ABRAHAM

full page →nih reporter ↗

Apr 6, 2026grant128d agoEMORY UNIVERSITY — Targeting androgen-driven resistance to immune checkpoint inhibitors in pancr...Emory University

CA grant. $402,401. PI: Kiranj Chaudagar

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF CALIFORNIA, SAN FRANCISCO — Interplay of heterosexual male-female partner microbiomes, Chlamydia trachoma...University of California San Francisco

AI grant. $816,421. PI: DEBORAH Anne DEAN

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF ILLINOIS AT CHICAGO — Elucidating The Immunoregulatory Role of Dendritic Cell Subsets in Periodonta...

DE grant. $320,660. PI: Araceli Maria Valverde

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF CALIFORNIA LOS ANGELES — Genetic and Gut Microbial Regulation of Indole-3 Propionate in Metabolic DiseaseUniversity of California Los Angeles

DK grant. $778,662. PI: Hooman Allayee

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF NEBRASKA MEDICAL CENTER — Reassessing West Nile virus action thresholds for improved disease control

AI grant. $436,157. PI: BRIAN David FOY

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF TEXAS AT AUSTIN — Mechanisms of the interplay between metabolism, chromatin regulation, and tra...

GM grant. $429,650. PI: Hong Qiao

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF MONTANA — Inter-strain recombinants of human cytomegalovirus as an in vitro model of in...

AI grant. $147,000. PI: BRENT J. RYCKMAN

full page →nih reporter ↗

Apr 6, 2026grant128d agoLSU HEALTH SCIENCES CENTER — Screening and validation of miRNA targets for neurogenic hypertension.

HL grant. $1,008,719. PI: Eric D Lazartigues

full page →nih reporter ↗

Apr 6, 2026grant128d agoUNIVERSITY OF PENNSYLVANIA — Elucidating the Mechanisms and Roles of RNA Editing and SensingUniversity of Pennsylvania

GM grant. $446,875. PI: Qin Li

full page →nih reporter ↗

← prev

page 1 of 8

Week of Apr 6, 2026